FDA holds hearing on access and safety as psychedelic drug approval looms

The Food and Drug Administration convened a public hearing to collect input on how emerging psychedelic medicines should be used, monitored, and continuously studied as a potential first approval approaches.

A central issue raised was patient access: if a psychedelic drug receives approval, the FDA must decide who is permitted to administer it and how those decisions will affect patients' ability to receive treatment.

Biotech firms such as Compass Pathways and Definium Therapeutics have shifted away from state‑run psychedelic therapy models, opting for supervised dosing sessions where a healthcare provider acts as a session monitor. Several hearing participants urged the agency to recognize the importance of the therapeutic relationship in these treatments.